Miyorel Tablet

Miyorel tablet is a pharmaceutical product manufactured by Sanofi in Turkey that combines two active ingredients: Metocarbamol (375 mg) and Paracetamol (300 mg). This medication belongs to a therapeutic class of drugs known for their analgesic, antipyretic, and muscle relaxant properties. The unique combination offers effective relief for various musculoskeletal conditions by addressing both pain and muscle spasms simultaneously. This article provides an in-depth examination of Miyorel’s composition, pharmacological properties, therapeutic applications, and safety considerations.

Composition and Pharmacological Properties

Miyorel tablet contains two primary active ingredients that work synergistically to provide pain relief and muscle relaxation. Understanding the mechanisms of action for each component helps explain the overall therapeutic effect of this medication.

Metocarbamol Component

Metocarbamol (375 mg per tablet) is a centrally acting muscle relaxant. Its primary mechanism of action involves inhibiting polysynaptic reflexes in the spinal cord and subcortical centers. Unlike direct-acting muscle relaxants, metocarbamol does not act directly on the contractile mechanism of striated muscle, motor end plates, or nerve fibers. Instead, it produces its effects through general central nervous system (CNS) depression, which helps relieve discomfort associated with painful musculoskeletal conditions.

The pharmacokinetic profile of metocarbamol shows plasma clearance ranging between 0.20 and 0.80 L/h/kg in healthy individuals, with a mean plasma elimination half-life of 1-2 hours. Approximately 46-50% of the drug binds to plasma proteins. However, in patients with cirrhosis, clearance may be reduced by approximately 70%, and the elimination half-life can be extended to about 3.38 hours.

Paracetamol Component

Paracetamol (300 mg per tablet), also known as acetaminophen, functions as an analgesic and antipyretic. Its mechanism of action primarily involves the inhibition of prostaglandin synthesis, with a predominant influence on the thermoregulation center in the hypothalamus. It appears to selectively inhibit cyclooxygenase (COX) activities in the brain, which contributes to its pain-relieving and fever-reducing capabilities. Paracetamol also enhances heat transfer, which helps in reducing fever.

Therapeutic Indications

Miyorel is prescribed for various conditions where both pain relief and muscle relaxation are beneficial. The medication targets acute conditions rather than chronic pain management.

Musculoskeletal Pain Management

Miyorel is particularly effective for treating pain resulting from injuries, strains, or overexertion. The dual action of its components provides comprehensive relief by addressing both the pain sensation and the underlying muscle tension. This makes it suitable for athletic injuries, workplace accidents, and other trauma-related pain.

Painful Muscle Contractions

The medication is indicated for painful muscle contractions resulting from sprains, fractures, or other causes. By reducing muscle spasms through the action of metocarbamol and alleviating pain through paracetamol, Miyorel helps patients recover more comfortably from these conditions.

Lower Back Pain (Lumbago)

Miyorel is frequently prescribed for lumbago, which refers to pain in the lower and middle parts of the back. This condition often involves both pain and muscle tension, making the combination of metocarbamol and paracetamol particularly suitable for treatment.

Other Indications

Additional conditions for which Miyorel may be prescribed include myalgia (muscle pain) and arthralgia (joint pain). The medication is most effective when used as part of a comprehensive treatment approach that may also include rest, physical therapy, and other measures.

Dosage and Administration

Miyorel is available in tablet form and is intended for oral administration. The medication should be taken according to the physician’s instructions.

Standard Dosage

While the search results don’t provide specific dosage instructions for Miyorel tablets, the medication is typically prescribed for adults and adolescents over 12 years of age. The tablet comes in packages of 20 or 40 tablets.

Special Populations

Caution should be exercised when administering Miyorel to patients with liver or kidney dysfunction. The medication is contraindicated for children under 12 years of age.

Contraindications

Miyorel should not be used in certain conditions due to potential risks or reduced efficacy.

Hypersensitivity

The medication is contraindicated in patients with known hypersensitivity to paracetamol, metocarbamol, or any of the tablet components.

Neurological Conditions

Patients with epilepsy or known brain damage should not use Miyorel. Additionally, the medication is contraindicated in patients with myasthenia gravis, as metocarbamol may inhibit the effect of anticholinesterase agents.

Age Restrictions

Miyorel is not recommended for children under 12 years of age.

Pregnancy and Lactation

The medication is contraindicated during pregnancy. Breastfeeding mothers should also avoid Miyorel, as metocarbamol passes into breast milk in small amounts.

Side Effects and Adverse Reactions

Like all medications, Miyorel may cause various side effects, though not everyone experiences them.

Category	Details
Common Side Effects	– Dizziness – Drowsiness – Nausea
Less Common Side Effects	– Headache – Blurred vision – Fever – Allergic reactions (urticaria/hives, skin rash)
Rare Adverse Effects	– Blood or cloudy urine – Hematological disorders – Acute liver necrosis (with excessive paracetamol doses)
Drug Interactions	– May interact with various medications, altering effects or increasing side effect risk
Hepatotoxicity Risk	– Increased when paracetamol is used with alcohol, barbiturates, anticonvulsants, or other liver enzyme inducers
Anticoagulant Interactions	– Long-term high-dose paracetamol may enhance anticoagulant effect
Other Interactions	– Anticholinergics (reduce paracetamol absorption) – Oral contraceptives (accelerate paracetamol excretion) – Urological medications (reduced effectiveness) – Pyridostigmine bromide (metocarbamol may inhibit effect)

Precautions and Warnings

Several precautions should be observed when using Miyorel to ensure safety and effectiveness.

Liver and Kidney Function

Miyorel should be used with caution in patients with liver or kidney dysfunction. Regular monitoring of liver function is advised during prolonged use.

CNS Depression

Due to the CNS depressant effect of metocarbamol, patients should be cautioned about the additive effects when used with alcohol or other CNS depressants.

Driving and Operating Machinery

Patients should be warned that Miyorel may cause drowsiness and impair the ability to drive or operate dangerous machinery.

Laboratory Test Interference

Metocarbamol may cause color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA).

Miyorel in Clinical Practice

Treatment Approach

Miyorel is most effective when used as part of a comprehensive treatment approach. While the medication provides symptomatic relief, addressing the underlying cause of muscle pain or spasm is essential for complete resolution.

Duration of Treatment

The maximum duration of treatment is typically 5-7 days unless otherwise directed by a healthcare provider. Prolonged use should be avoided without medical supervision due to potential risks associated with extended use of paracetamol.

Summary Table

Conclusion

Miyorel tablet represents an effective combination therapy for acute musculoskeletal pain and muscle spasms. By combining the muscle relaxant properties of metocarbamol with the analgesic and antipyretic effects of paracetamol, it provides comprehensive relief for patients suffering from various painful conditions involving muscle tension. However, like all medications, it should be used with appropriate caution, particularly regarding potential side effects, drug interactions, and contraindications. Healthcare providers should evaluate each patient individually to determine if Miyorel is an appropriate treatment option based on their specific medical history and condition.